Performance Output With Haptics - Evaluating Athlete Response and Unrealized Potential
Launched by SUPERPATCH LIMITED LLC · May 20, 2024
Trial Information
Current as of February 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Emerging technologies that use haptic (skin pressure) technology have been studied and have shown positive improvements in stress levels, balance, sleep, and pain. The VICTORY patch (SuperPatch Company, Toronto, Canada) that also incorporates this technology has shown anecdotal promise to improve athlete performance. With the tools currently in use at the University of Arizona, team coaches and physicians can measure the true impact of neuromuscular changes suggested by the VICTORY patch. This study will measure quadriceps and hamstring strength in isolation as well as peak output in jumpin...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adults 18 to 30, inclusive
- • 2. Able to provide written informed consent
- • 3. Have received a VICTORY Patch if in treatment group.
- • 4. Is an athlete on a University of Arizona Varsity Athletic Team
- • 5. Agree to having physical activity objectively measured for physical activity, as well as attendance, and participation in intervention.
- • 6. Agree to place an adhesive patch on their skin, as instructed, based on selection group.
- Exclusion Criteria:
- • 1. Use of drugs of abuse (illicit or prescription)
- • 2. Have an implanted device, or wears, or adheres any electrical device to the body during the study, other than a hearing aid.
- • 3. Any current medical or musculoskeletal injury that would prohibit athletic participation
- • 4. Any significant injuries in the last month prior to the intervention that may impact tested performance measures.
- • 5. New injuries that occur during the course of study testing that may impact performance measures.
Trial Officials
Mark Sakr, DO
Principal Investigator
University of Arizona
About Superpatch Limited Llc
Superpatch Limited LLC is an innovative clinical trial sponsor dedicated to advancing healthcare through the development of cutting-edge transdermal delivery systems. With a focus on creating effective and patient-friendly therapeutic solutions, Superpatch combines advanced technology with rigorous clinical research to enhance drug delivery methods. The company is committed to ensuring the highest standards of safety and efficacy in its trials, while fostering collaboration with healthcare professionals and regulatory bodies. Through its pioneering approach, Superpatch Limited LLC aims to improve patient outcomes and contribute to the future of medical treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0